Drug shows promise for Ebola virus treatment in primates

For the first time, scientists have successfully treated monkeys infected with the deadly Ebola virus. Ebola causes hemorrhagic fever that kills up to 80 percent of humans infected with the virus.

These findings, published in the December 13th issue of THE LANCET, represent an important step in the search for a treatment strategy for Ebola. Currently no effective therapies are available.

In the study, Thomas W. Geisbert and colleagues from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) injected 12 rhesus macaques with Ebola virus. Nine of the animals received a drug called recombinant nematode anticoagulant protein c2 (rNAPC2), while the remaining three were untreated.

In the treatment group, monkeys received rNAPC2 either immediately after Ebola infection, or 24 hours later, and continued to receive it daily for up to fourteen days. Three of the nine monkeys survived, and death was slowed by several days in the remaining six. All three untreated animals died.

Previous attempts to use antiviral drugs to treat Ebola have demonstrated success in mice and guinea pigs, but not in primates. Geisbert's team approached the problem a different way--by focusing on the symptoms triggered by the virus, rather than the virus itself.

Ebola causes coagulopathy, or abnormal blood clotting, which ultimately leads to massive hemorrhage and death. Studies at USAMRIID suggest that macrophages, a type of white blood cell, play an important role in this process. When a host is infected with Ebola virus, the macrophages express a clotting protein, called tissue factor, on their surfaces. These cells are then attracted to the blood as it flows through the body, forming localized clots that pave the way for abnormal bleeding.

Using rNAPC2, according to Geisbert, essentially blocks the harmful effects of tissue factor. The drug is already being evaluated to treat coronary problems, and has a demonstrated p

Contact: Caree Vander Linden
US Army Medical Research Institute of Infectious Diseases

Page: 1 2

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: